兰卫医学
(301060)
| 流通市值：43.29亿 | | | 总市值：48.14亿 |
| 流通股本：3.60亿 | | | 总股本：4.01亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 591,643,227.81 | 287,160,602 | 1,448,033,298.51 | 1,102,095,711.13 |
| 营业总成本 | 557,625,336.79 | 271,327,012.7 | 1,426,919,718.5 | 1,065,770,911.06 |
| 其他经营收益 | | | | |
| 营业利润 | 85,400,446.57 | 46,231,244.4 | 14,911,743.43 | 24,969,643.71 |
| 利润总额 | 85,239,227.22 | 45,961,769.87 | 10,531,305.23 | 21,448,233.03 |
| 净利润 | 68,552,669.65 | 38,457,008.52 | -15,422,510.31 | 10,207,252.28 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 68,552,669.65 | 38,457,008.52 | -15,422,510.31 | 10,207,252.28 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,646,744,478.1 | 1,831,983,432.29 | 1,751,811,605.65 | 1,843,699,090.36 |
| 非流动资产: | | | | |
| 非流动资产合计 | 500,408,083.22 | 516,417,380.05 | 540,400,491.69 | 587,059,358.99 |
| 资产总计 | 2,147,152,561.32 | 2,348,400,812.34 | 2,292,212,097.34 | 2,430,758,449.35 |
| 流动负债: | | | | |
| 流动负债合计 | 407,071,294.36 | 561,258,039.28 | 531,175,528.7 | 598,869,926.26 |
| 非流动负债: | | | | |
| 非流动负债合计 | 102,844,035.16 | 105,073,555.65 | 116,211,640.09 | 161,558,188.64 |
| 负债合计 | 509,915,329.52 | 666,331,594.93 | 647,387,168.79 | 760,428,114.9 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,550,951,706.51 | 1,585,796,616.71 | 1,548,475,038.65 | 1,577,756,499.98 |
| 股东权益合计 | 1,637,237,231.8 | 1,682,069,217.41 | 1,644,824,928.55 | 1,670,330,334.45 |
| 负债和股东权益合计 | 2,147,152,561.32 | 2,348,400,812.34 | 2,292,212,097.34 | 2,430,758,449.35 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 711,693,164.82 | 353,674,978.94 | 1,667,373,100.89 | 1,224,053,420.24 |
| 经营活动现金流出小计 | 558,838,394.34 | 251,541,074.87 | 1,398,519,320.98 | 1,052,294,528.89 |
| 经营活动产生的现金流量净额 | 152,854,770.48 | 102,133,904.07 | 268,853,779.91 | 171,758,891.35 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,041,095,007.09 | 1,105,154,161.86 | 1,923,471,096.36 | 1,204,425,824.99 |
| 投资活动现金流出小计 | 1,989,871,928.26 | 1,046,607,905.72 | 2,046,355,819.15 | 1,231,042,830.56 |
| 投资活动产生的现金流量净额 | 51,223,078.83 | 58,546,256.14 | -122,884,722.79 | -26,617,005.57 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | 50,000,000 | 50,100,000 |
| 筹资活动现金流出小计 | 140,848,881.8 | 14,179,537.7 | 323,731,178.66 | 277,707,418.1 |
| 筹资活动产生的现金流量净额 | -140,848,881.8 | -14,179,537.7 | -273,731,178.66 | -227,607,418.1 |
| 汇率变动对现金及现金等价物的影响 | -3,517 | -1,570.96 | -29,451.71 | -27,346.41 |
| 现金及现金等价物净增加额 | 63,225,450.51 | 146,499,051.55 | -127,791,573.25 | -82,492,878.73 |
| 期末现金及现金等价物余额 | 761,181,201.83 | 844,454,802.87 | 697,955,751.32 | 743,254,445.84 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 63,225,450.51 | - | -127,791,573.25 | - |